Skip to content
Companies

Cyclacel Pharmaceuticals

Cell cycle drugs for drug-resistant cancers

Raised to date

$1M

across 3 Form D filings

Still open
$25M
Investors
1
Last filed
Mar 25, 2025

About

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment through pioneering biologically-based therapies. The company is firmly committed to addressing the pressing challenge of drug resistance in cancer treatment by developing innovative medications that work by reactivating cell death mechanisms.

Cyclacel stands out through its focused research on cell cycle biology and its commitment to addressing unmet medical needs in oncology and hematology, thereby improving patient outcomes.

Funding

$25M round, first sold Feb 2025Nothing sold yetFeb 20252026
Now
  • EquityFiled Mar 25, 2025Form D
    $1M/ $1M
  • EquityFiled Feb 14, 2025Form D
    None sold/ no target
  • EquityFiled Feb 14, 2025Form D
    None sold/ $25M

Product

Novel Oncology Treatments

Oncology

Cyclacel Pharmaceuticals develops a range of therapeutic candidates aimed at overcoming cancer drug resistance utilizing targeted approaches in cell cycle biology, transcriptional regulation, and mitosis biology. These innovative treatments are designed to tackle cancers that have proven challenging for conventional therapies.

  • Targeted cell cycle mechanisms
  • Reactivation of cell death pathways
  • Focus on cancer drug resistance

Built for

Oncology and hematology patients

People on file